b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31425886</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1876-7737</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>208</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>09</Month>\n                        <Day>30</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of proteomics</Title>\n                <ISOAbbreviation>J Proteomics</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>103487</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S1874-3919(19)30259-3</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jprot.2019.103487</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Little is known about fibrin clot composition in relation to its structure and lysability. We investigated plasma clots protein composition and its associations with clot properties.</AbstractText>\n                <AbstractText Label="METHODS">We studied 20 healthy subjects aged 31-49\xe2\x80\xafyears in whom plasma fibrin clot permeability (K<sub>s</sub>) and clot lysis time (CLT) were determined. A proteomic analysis of plasma fibrin clots was based on quantitative liquid chromatography-mass spectrometry.</AbstractText>\n                <AbstractText Label="RESULTS">Among 494 clot-bound proteins identified in all clots, the highest concentrations were for fibrinogen chains (about 64% of the clot mass) and fibronectin (13%). \xce\xb1<sub>2</sub>-antiplasmin (2.7%), factor XIIIA (1.2%), complement component C3 (1.2%), and histidine-rich glycoprotein (HRG, 0.61%) were present at relatively high concentrations. Proteins present in concentrations &lt;0.5% included (pro)thrombin, plasminogen, apolipoproteins, or platelet factor 4 (PF4). Fibrinogen-\xce\xb1 and -\xce\xb3 chains were associated with age, while body-mass index with clot-bound apolipoproteins (all p\xe2\x80\xaf&lt;\xe2\x80\xaf.05). K<sub>s</sub> correlated with fibrinogen-\xce\xb3 and PF4 amounts within plasma clots. CLT was associated with fibrinogen-\xce\xb1 and -\xce\xb3, PF4, and HRG (all p\xe2\x80\xaf&lt;\xe2\x80\xaf.05).</AbstractText>\n                <AbstractText Label="CONCLUSIONS">This study is the first to show associations of two key measures of clot properties with protein content within plasma clots, suggesting that looser fibrin clots with enhanced lysability contain less fibrinogen-\xce\xb3 chain, platelet-derived PF4, and HRG.</AbstractText>\n                <AbstractText Label="SIGNIFICANCE">Our study for the first time suggests that more permeable fibrin clots with enhanced lysability contain less fibrinogen-\xce\xb3 chain, platelet-derived factor 4, and histidine-rich glycoprotein, which is related to accelerated clot lysis. The current findings might have functional consequences regarding clot structure, stability, and propagation of thrombin generation, and detailed proteomic analysis of clots in various disorders opens new perspective for coagulation and fibrin research.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Z\xc4\x85bczyk</LastName>\n                    <ForeName>Micha\xc5\x82</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Stachowicz</LastName>\n                    <ForeName>Aneta</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chair of Pharmacology, Jagiellonian University Medical College, Krakow, Poland; Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Natorska</LastName>\n                    <ForeName>Joanna</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Olszanecki</LastName>\n                    <ForeName>Rafa\xc5\x82</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Chair of Pharmacology, Jagiellonian University Medical College, Krakow, Poland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wi\xc5\x9bniewski</LastName>\n                    <ForeName>Jacek R</ForeName>\n                    <Initials>JR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Undas</LastName>\n                    <ForeName>Anetta</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technology, John Paul II Hospital, Krakow, Poland. Electronic address: mmundas@cyf-kr.edu.pl.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>16</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Netherlands</Country>\n            <MedlineTA>J Proteomics</MedlineTA>\n            <NlmUniqueID>101475056</NlmUniqueID>\n            <ISSNLinking>1874-3919</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Clot</Keyword>\n            <Keyword MajorTopicYN="Y">Clot properties</Keyword>\n            <Keyword MajorTopicYN="Y">Fibrin</Keyword>\n            <Keyword MajorTopicYN="Y">Proteomics</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>27</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>02</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>8</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31425886</ArticleId>\n            <ArticleId IdType="pii">S1874-3919(19)30259-3</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.jprot.2019.103487</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'